Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Musculoskeletal Diseases 1Joint Diseases 1Arthritis, Rheumatoid 1Arthritis 1

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × upadacitinib × Clear all
NCT01960855 2021-08-24

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

AbbVie

Phase 2 Completed
276 enrolled 14 charts

Arthritis, Arthritis, Rheumatoid, Joint Diseases, Musculoskeletal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡